What ADHD Actually Is: A Modern Clinical Explanation

ADHD is one of the most studied conditions in psychiatry and one of the most misunderstood in everyday conversation. This article sets out what it actually is, where the diagnostic criteria come from, what is happening in the brain, how it is recognised in the UK, and what the evidence says works. No jargon dump, no caricatures.

What ADHD is, in clinical terms

Attention deficit hyperactivity disorder is a neurodevelopmental condition. That word matters. It means the differences are present from early development and reflect how the brain is wired, not a behaviour someone has chosen or a phase that will simply pass ^{[1, 2]}.

The two main diagnostic frameworks used in the UK are the DSM-5-TR, published by the American Psychiatric Association in 2022, and the ICD-11, maintained by the World Health Organization ^{[7, 8]}. Both describe the same core picture: a persistent pattern of inattention, hyperactivity and impulsivity that is more pronounced than expected for someone's age, shows up in more than one setting, started in childhood, and causes meaningful difficulty in daily life.

A few features are worth holding onto:

• ADHD is dimensional, not categorical. Traits exist on a continuum across the population. Clinical ADHD sits at the end of that continuum where the traits become persistent, pervasive and impairing.
• ADHD is not a problem of effort. People with ADHD often expend significantly more effort than peers to achieve the same outcomes.
• ADHD is not just hyperactivity. The inattentive presentation is just as real and is the one most often missed, particularly in girls, women and quieter adults.

NICE guideline NG87 is the UK reference standard for diagnosis and management. It frames ADHD as a long-term condition that needs specialist assessment and, where appropriate, treatment that combines psychoeducation, environmental adjustments, psychological support and medication ^[1].

The three presentations

DSM-5-TR groups ADHD into three presentations based on which traits dominate in the past six months ^[7]:

• Predominantly inattentive presentation. Difficulty sustaining attention on tasks that are not intrinsically interesting, losing track of details, forgetfulness in daily activities, and trouble with organisation and follow-through. This is the presentation most commonly missed in school and often labelled as "daydreamy" or "lazy".
• Predominantly hyperactive-impulsive presentation. Restlessness, fidgeting, talking over others, acting before thinking, and difficulty with quiet activities. More visible in young children. In adults the physical hyperactivity often softens into internal restlessness.
• Combined presentation. Significant traits across both clusters. This is the most common presentation seen in clinic.

The presentation can shift across the lifespan. A child diagnosed with the combined presentation at age eight may meet criteria for the inattentive presentation at thirty. The underlying neurobiology has not changed; the way it shows up has ^[2].

What is happening in the brain

ADHD is, at its core, a difference in the brain's self-regulation systems. Most current models centre on two neurotransmitters, dopamine and noradrenaline, and their role in the prefrontal cortex and the networks that connect it to the rest of the brain ^[2].

These networks are responsible for what clinicians call executive function: the set of mental processes that let us hold information in mind, switch between tasks, plan, prioritise, inhibit impulses, regulate emotion and start things that are boring but necessary. In ADHD, these processes do not work less hard. They work less reliably, particularly when the task lacks novelty, urgency, challenge or personal interest ^[2].

This is why someone with ADHD can hyperfocus for six hours on a passion project, then be unable to start a ten-minute admin task. The system is not broken in a uniform way; it responds disproportionately to interest and stimulation. Clinically, this is sometimes described as an interest-based nervous system, although the formal term is dysregulated reward and arousal processing.

A few brain findings have held up across large studies and meta-analyses ^[2]:

• Subtle differences in the volume and activity of regions including the prefrontal cortex, basal ganglia and cerebellum.
• Altered connectivity between the default mode network and task-positive networks, which can manifest as mind-wandering at the wrong moments.
• Differences in the dopamine and noradrenaline pathways that stimulant and non-stimulant medications target.

None of these findings are individually diagnostic. There is no brain scan that confirms ADHD. The diagnosis is clinical, made by an appropriately trained professional using a detailed interview, developmental history and standardised tools ^[1].

Where ADHD comes from

ADHD is one of the most heritable conditions in psychiatry. Twin studies consistently put heritability at around 70 to 80 percent across the lifespan ^[2]. If a parent has ADHD, the probability of a child having ADHD is meaningfully higher than the population baseline.

Genome-wide association studies have identified specific genetic loci associated with ADHD, and the genetic architecture overlaps with other conditions including autism, depression and educational outcomes ^[4]. ADHD is polygenic, meaning many genes contribute small effects, rather than caused by a single "ADHD gene".

Environmental factors matter too, particularly early-life ones such as prematurity, low birth weight, prenatal exposure to alcohol or nicotine, and significant adversity in early childhood ^[2]. These do not cause ADHD on their own; they interact with genetic vulnerability.

A few things ADHD is not caused by, despite the popular myths:

• It is not caused by parenting style. Parenting affects how ADHD plays out, but does not create it.
• It is not caused by sugar. Decades of trials have not shown this to be true ^[2].
• It is not caused by screen time or phones. ADHD has been described for over a century and the genetic data is clear.

Recognising that the condition is largely biological is not a counsel of despair. It is the opposite. It moves the conversation away from blame and towards practical support.

How common ADHD actually is

In children worldwide, pooled prevalence sits at around 5 to 7 percent, with some methodological variation ^[3]. In adults, the global meta-analytic estimate is around 2.5 to 5 percent depending on how strictly the criteria are applied and how the interview is conducted ^[5].

UK numbers track closely to the international figures. NICE NG87 cites a UK prevalence in children of approximately 5 percent and in adults of approximately 3 to 4 percent ^[1]. ADHD does not disappear at age 18. The current consensus is that most people who meet criteria as children continue to experience meaningful traits as adults, although the picture often shifts from external hyperactivity to inner restlessness, time blindness, emotional dysregulation and chronic difficulty with self-direction ^[2].

The current wave of adult ADHD assessments in the UK is not a sudden epidemic. It is a generation of people, particularly women, who were missed in childhood reaching the point where they have the language and the access to ask the question.

Why ADHD is frequently missed

A few specific reasons account for most missed diagnoses:

• Inattentive presentation without hyperactivity. Quiet, daydreamy children rarely trigger school concerns until grades or anxiety start sliding ^[2].
• High IQ or strong early support masking the difficulty. Many adults with ADHD coast through school on intelligence and structured environments, then meet difficulty at university, in their first job, or when they become a parent.
• Co-occurring anxiety or depression taking the spotlight. The presenting complaint is the mood symptom; the underlying ADHD never gets asked about ^{[1, 2]}.
• Gendered stereotypes. The picture of a disruptive boy still dominates lay perception. Girls and women with ADHD often present with internalised symptoms and are diagnosed years or decades later ^[2].

This pattern of late and missed diagnosis is one of the strongest arguments for clinicians to take adult enquiry seriously, and for the public to understand that ADHD does not have a stereotypical face.

How ADHD is diagnosed in the UK

NICE NG87 sets out the assessment standard. A diagnosis should be made by a specialist clinician with training and experience in ADHD, on the basis of a full clinical interview that covers ^[1]:

• A full symptom history aligned with DSM-5-TR or ICD-11 criteria.
• A developmental history, ideally including a childhood informant where possible.
• Information about current functioning across multiple settings (work, education, home, relationships).
• A review of mental and physical health for co-occurring conditions and differential diagnosis.

Structured tools support, rather than replace, the clinical interview. For adults, the DIVA-5 is the most commonly used semi-structured interview. Self-report scales such as the ASRS provide screening signal. Objective tests such as QbCheck measure attention, impulsivity and motor activity in a controlled task and can add corroborating information, but no single test confirms or rules out ADHD on its own ^[1].

Access in the UK comes through three main routes:

• NHS via GP referral. The default route. Waiting times in many regions are long and can run into years.
• Right to Choose in England. A legal entitlement that allows patients in England to request referral to any provider holding an NHS contract for ADHD assessment, often with shorter waits. How Right to Choose actually works is worth understanding before the GP appointment.
• Private assessment. Self-funded with a CQC-registered provider. Faster, paid out of pocket, and with the option of subsequent shared care depending on the local ICB. NeuroFX offers private adult ADHD assessment along these lines; what private assessment actually looks like in the UK covers the timeline, pricing and outcomes in detail.

Scotland, Wales and Northern Ireland do not have Right to Choose in the same form, so the pathway there sits between NHS referral and private self-funding.

What treatment actually looks like

NICE recommends a layered approach ^[1]:

• Psychoeducation first. Understanding the condition is itself part of treatment. People who know how their brain works tend to design better strategies for themselves.
• Environmental and behavioural adjustments. Changes at school, university or work, sleep hygiene, exercise, structured external systems, and reasonable adjustments under the Equality Act 2010.
• Psychological support where indicated. For co-occurring anxiety, depression, low self-esteem, or trauma. CBT adapted for ADHD has evidence in adults.
• Medication where appropriate. Stimulants (methylphenidate and lisdexamfetamine in the UK) are first-line for most adults and many children. Non-stimulants (atomoxetine, guanfacine) are alternatives where stimulants are unsuitable. A network meta-analysis in Lancet Psychiatry found stimulants the most effective option in adults, with methylphenidate first-line in children based on tolerability ^[6]. The practical detail of ADHD medication and titration, including shared care with NHS GPs, is covered in its own article.

Medication is not a moral question, and it is not a magic eraser. For most people who respond well, it lifts the floor: the same tasks become possible, the gap between intention and action narrows, and other supports start to actually land. Side effects are real and titration takes time, often three months or more to settle.

What this means in practice

If you are recognising yourself or your child in this article:

• Take the question seriously, but do not over-diagnose from the internet. ADHD content online is a mix of accurate clinical material and viral generalisations. Treat it as a prompt for a proper conversation, not a verdict.
• Track the pattern. Write down where, when and how the difficulties show up. A clinician will ask for examples across multiple settings and across the lifespan. Patchy memory and old school reports help.
• Talk to your GP. Ask specifically for a referral for an ADHD assessment. Mention Right to Choose if you are in England and you want to explore that route.
• Consider private assessment if waiting times are a barrier. Use a CQC-registered provider with specialist ADHD experience. Avoid online "diagnostic quizzes" sold as assessment.
• Do not start with medication in your mind as the only outcome. A good assessment ends with a clear picture and a personalised plan. Medication is one part, not the whole.

When to speak to a professional

Speak to your GP if traits are persistent, affect more than one area of life, and are not better explained by something else. Seek same-day support if you or your child are experiencing thoughts of self-harm, severe mood symptoms, or a mental health crisis. If you are in the UK and need urgent help, call 111 or, in an emergency, 999.

ADHD assessment can be accessed via the NHS through GP referral, via Right to Choose in England, or privately. NeuroFX offers CQC-registered private ADHD assessment and prescribing for adults and children aged 6 and upwards from our Bedford clinic, with shared care handover to NHS GPs where the local ICB accepts it. The right route is the one that fits your situation; the important thing is getting a proper clinical answer rather than living indefinitely with the question.

Sources

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
2. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.
3. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology. 2014;43(2):434-442.
4. Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics. 2019;51:63-75.
5. Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of Global Health. 2021;11:04009.
6. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association Publishing; 2022.
8. World Health Organization. International Classification of Diseases, 11th Revision (ICD-11). https://icd.who.int/
9. NHS. Attention deficit hyperactivity disorder (ADHD). https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/